- Open Access
Design of a novel quantitative PCR (QPCR)-based protocol for genotyping mice carrying the neuroprotective Wallerian degeneration slow (Wld s ) gene
© Wishart et al; licensee BioMed Central Ltd. 2007
Received: 12 September 2007
Accepted: 30 October 2007
Published: 30 October 2007
Mice carrying the spontaneous genetic mutation known as Wallerian degeneration slow (Wld s ) have a unique neuroprotective phenotype, where axonal and synaptic compartments of neurons are protected from degeneration following a wide variety of physical, toxic and inherited disease-inducing stimuli. This remarkable phenotype has been shown to delay onset and progression in several mouse models of neurodegenerative disease, suggesting that Wld s -mediated neuroprotection may assist in the identification of novel therapeutic targets. As a result, cross-breeding of Wld s mice with mouse models of neurodegenerative diseases is used increasingly to understand the roles of axon and synapse degeneration in disease. However, the phenotype shows strong gene-dose dependence so it is important to distinguish offspring that are homozygous or heterozygous for the mutation. Since the Wld s mutation comprises a triplication of a region already present in the mouse genome, the most stringent way to quantify the number of mutant Wld s alleles is using copy number. Current approaches to genotype Wld s mice are based on either Southern blots or pulsed field gel electrophoresis, neither of which are as rapid or efficient as quantitative PCR (QPCR).
We have developed a rapid, robust and efficient genotyping method for Wld s using QPCR. This approach differentiates, based on copy number, homozygous and heterozygous Wld s mice from wild-type mice and each other. We show that this approach can be used to genotype mice carrying the spontaneous Wld s mutation as well as animals expressing the Wld s transgene.
We have developed a QPCR genotyping method that permits rapid and effective genotyping of Wld s copy number. This technique will be of particular benefit in studies where Wld s mice are cross-bred with other mouse models of neurodegenerative disease in order to understand the neuroprotective processes conferred by the Wld s mutation.
The Wallerian degeneration slow gene (Wld s ) protects axons and synapses in both the CNS and PNS from injury-, neurotoxin- and inherited neurodegenerative conditions [1–5]. These properties have been shown to mitigate disease progression in several mouse models of neurodegenerative disease, including certain forms of motor neuron disease [[6, 7]; but see ], gracile axonal dystrophy , Parkinson's disease , transient global cerebral ischemia , and myelin-related axonopathies . Moreover, this remarkable neuroprotective phenotype has been transferred to other species, including rats and Drosophila [13, 14]. The ability to deliver the Wld s gene to wild-type cells and confer neuroprotection across different species offers the possibility of developing Wld s -based therapeutics for treating human disease [5, 13, 15–17].
Evidence from studies of natural mutant mice and mice transgenic for Wld S suggests that its neuroprotective effect is strongly gene-dose dependent. For instance, reducing WldS protein expression by 50% removes almost all of the protective effect on motor nerve terminals while further reductions in the expression level additionally weakens the protection of distal axons (3, 18). As cross-breeding of Wld s mice with other mouse models of neurodegenerative disease becomes more commonplace, the ability to identify and distinguish wild-type from heterozygous and homozygous mice becomes more critical.
The Wld S mutation is a triplication of a region already present in the wild-type animal, encoding a fusion protein comprising the full length of nicotinamide mononucleotide adenylyltransferase 1 (Nmnat1; a NAD+ synthesizing enzyme) coupled by a unique 18-amino acid sequence to the N-terminal 70 residues of the ubiquitination enzyme Ube4b [18, 19]. Therefore, the means available to assess the number of mutant Wld S alleles present are by using either, the strength of the neuroprotective phenotype (for instance, based on protection of axons and synapses following a surgical nerve lesion) or detecting the copy number of the mutation. As well as an inefficient use of resources, the first approach is not suitable for genotyping on ethical and temporal grounds: an invasive procedure (nerve injury or biopsy) is required to test for strength of neuroprotection over a period of several days and provides only an indirect and semi-quantitative measure. The second approach is therefore the only one suitable for exact genotyping purposes.
Initially, attempts to PCR across the chimeric boundary were unreliable due to the very high GC content at that point in the sequence . Some success was found through the use of Southern blots in identifying homozygous animals from heterozygous animals as it can be used to some extent to distinguish the genotype by band intensity . However, Southern blotting proved to be an inefficient method for this type of genotyping as the results were often influenced by the need for equivalent loading concentrations, inconsistent DNA digestions, problems with blotting efficiency, and other factors that affected the quantifiable intensity of blots, their signal-noise ratio and the ability of the researcher to distinguish between samples on a film. A more robust method for genotyping Wld S mice was also reported by Mi and colleagues  based on Pulsed Field Gel Electrophoresis (PFGE). The PFGE method is based on fragment size rather than band intensity. Problems with this approach include the requirement for post-mortem material (not ideal for cross-breeding programs), time taken to obtain data and the requirement for the use of radio-labelled probes.
Here we report the development of a novel QPCR genotyping method that will allow rapid and effective genotyping of Wld s copy number.
Results and discussion
Quantitative PCR (QPCR) on genomic DNA for genotyping Wld s mice
C57BL/6J and C57BL/Wlds mice were obtained from Harlan UK and, where required were cross-bred to obtain F1 mice, heterozygous for Wlds. Ear punches were taken from mice between 1 and 4 months of age (N = 36 of confirmed genotype, N = 91 of unknown genotype). Tail tips were taken from transgenic rat lines Tg23 (N = 10) and Tg79 (N = 14). The investigator carrying out the QPCR screen was always blinded to the genotype of each tissue sample.
Genomic DNA was extracted using a modified proteinase K digestion/isopropanol precipitation protocol . Tissue was incubated in tail lysis buffer (100 mM Tris-HCl, pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl, 100 μg/ml Proteinase K). Samples were incubated overnight at 55°C. Lysed tissue was vortexed for 1 minute and spun at 15800 g for 10 minutes to remove hair and bone. The supernatant was decanted into a new tube and isopropanol was added (equal volume to the tail lysis buffer used earlier). The solutions were inverted until a white precipitate was seen. The solution was centrifuged and the pelleted DNA was washed with 70% ethanol and air dried before it was resuspended in an appropriate volume of 1 × TE buffer. For example, a 5 mm length of tail tip was digested and the DNA was finally resuspended in 50 μl of TE buffer and then stored at -20°C as a stock solution.
Wlds forward GGCAGTGACGCTCAGAAATTC
Wlds reverse GTTCACCAGGTGGATGTTGCT
Wlds probe TCTACGAGTCCGATGTGCTGTGGAGACA
β-Tubulin forward GCCAGAGTGGTGCAGGAAATA
β-Tubulin reverse TCACCACGTCCAGGACAGAGT
β-Tubulin probe CTGGGCAAAGGGCCACTACACAGAGG
The optimal primer concentrations used were 900 nM and the optimal probe concentration was found to be 250 nM. The PCR mix (TaqMan universal PCR master mix, no amperase UNG from ABI part # 4364341) was prepared according to the manufacturer's instructions. 1 μl of DNA was used at a concentration of 1:200 dilution (in TE buffer) of the original stock sample for each reaction. All reactions were carried out in triplicate on an ABI Prism 7000 sequence detection system using Applied Biosystems' standard thermal cycling parameters.
Plotting the ΔCt against animals of known genotype in a box and whisker plot (N = 36) allows the illustration of 95% confidence limits for each genotype (Figure 4). When plotting a scatter of the results for all of the animals of unknown genotype (N = 91) there was a clear banding into the 3 genotypes as demonstrated by the box and whisker plot of animals of known genotype (Figure 4). Only one sample fell outwith the 95% confidence limits for all of the plotted genotypes shown (Figure 4). In such circumstances, the genotyping for this particular sample should be considered invalid. The Wld s status of a representative set of unknown genotype animals whose identity was determined by QPCR was successfully confirmed using breeding records, Southern blotting techniques and subsequent experiments where the neuroprotective phenotype was revealed by nerve lesion and the use of morphological techniques (data not shown).
Determining copy number in transgenic animals
Transgenic animals (mice and rats) have been generated which express the Wld s chimeric gene [13, 18]. These animals show a strong neuroprotective phenotype. As it has previously been shown that the Wld s neuroprotective phenotype is dose-dependent (see above), it is therefore of interest to determine the number of copies which have been integrated into the genome of these transgenic animals.
It is especially important to measure Wld S copy number and expression level before making conclusions about its effects when attempting to transfer protective benefits to models of disease. For instance, two reports suggest little or no mitigation of disease onset or progression after crossbreeding Wld S mice with mouse models of amyotrophic lateral sclerosis (8,15); but it is presently unclear whether these reports fully accounted for the known, weak synaptic-protective effects of the Wld S gene in heterozygous and aged mice (3,18).
The QPCR genotyping method we report here facilitates accurate, rapid and effective genotyping of Wld s copy number in both spontaneous mutant mice and transgenic animals expressing Wld s , representing an improved, cost effective and more efficient general purpose method than PFGE, the most accurate alternative method reported thus far. This methodology should be of interest to groups working on other mutations which are difficult to genotype as the DNA does not need to be accurately quantified before use. This is because the methodology works by examining ratios between PCR product of interest and controls rather than absolute levels. It is also applicable to smaller tissue samples such as ear punches. This technique will be of particular benefit for current and future studies where Wld s mice or their transgenic equivalents, are being crossed with other strains, and especially relevant for studies attempting to understand the relationship between gene-dosage of the Wld s mutation and the effectiveness of its neuroprotective phenotype.
The authors would like to thank Derek Thomson for expert technical assistance. This work was supported by grants from the BBSRC (TMW/THG/MPC/MJS), MRC (RRR) and the Wellcome Trust (MPC/RRR/MJS).
- Lunn R, Perry VH, Brown MC, Rosen H, Gordon S: Absence of wallerain degeneration does not hinder regeneration in peripheral nerve. European Journal of Neuroscience. 1989, 1: 27-33. 10.1111/j.1460-9568.1989.tb00771.x.View ArticlePubMedGoogle Scholar
- Ribchester RR, Tsao JW, Barry JA, Asgari-Jirhandeh N, Perry VH, Brown MC: Persistance of neuromuscular junctions after axotomy in mice with slow Wallerian degeneration (C57BL/Wlds). European Journal of Neuroscience. 1995, 7: 1641-1650. 10.1111/j.1460-9568.1995.tb01159.x.View ArticlePubMedGoogle Scholar
- Gillingwater TH, Thomson D, Mack TG, Soffin EM, Mattison RJ, Coleman MP, Ribchester RR: Age dependant synapse withdrawal at axotomised neuromuscular junctions in Wld(s) mutant and Ube4b/Nmnat transgenic mice. J Physiol. 2002, 543: 739-755. 10.1113/jphysiol.2002.022343.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang MS, Davis AA, Culver DG, Glass JD: Wlds mice are resistant to paclitaxel (Taxol) neuropathy. Ann Neurol. 2002, 52: 442-447. 10.1002/ana.10300.View ArticlePubMedGoogle Scholar
- Gillingwater TH, Ingham CA, Parry KE, Wright AK, Haley JE, Wishart TM, Arbuthnott GW, Ribchester RR: Delayed synaptic degeneration in the CNS of Wlds mice after cortical lesion. Brain. 2006, 129: 1546-1556. 10.1093/brain/awl101.View ArticlePubMedGoogle Scholar
- Ferri A, Sanes JR, Coleman MP, Cunningham JM, Kato AC: Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motorneurone disease. Current Biology. 2003, 13: 669-673. 10.1016/S0960-9822(03)00206-9.View ArticlePubMedGoogle Scholar
- Fischer LR, Culver DG, Davis AA, Tennant P, Wang M, Coleman M, Asress S, Adalbert R, Alexander GM, Glass JD: The WldS gene modestly prolongs survival in the SOD1G93A fALS mouse. Neurobiol Dis. 2005, 19: 293-300. 10.1016/j.nbd.2005.01.008.View ArticlePubMedGoogle Scholar
- Vande Velde MM, Garcia ML, Yin X, Trapp BD, Cleveland DW: The neuroprotective factor Wlds does not attenuate mutant SOD1-mediated motor neurone disease. Neuromolecular Ned. 2004, 5: 193-203. 10.1385/NMM:5:3:193.View ArticleGoogle Scholar
- Mi W, Beirowski B, Gillingwater TH, Adalbert R, Wagner D, Grumme D, Osaka H, Conforti L, Arnhold S, Addicks K, Wada K, Ribchester RR, Coleman MP: The slow Wallerian degeneration gene, WldS, inhibits axonal spheroid pathology in gracile axonal dystrophy mice. Brain. 2005, 128: 405-16. 10.1093/brain/awh368.View ArticlePubMedGoogle Scholar
- Sajadi A, Schneider BL, Aebischer P: Wlds-mediated protection of dopinergic fibres in an animal model of Parkinson disease. Current Biology. 2004, 14: 326-330.View ArticlePubMedGoogle Scholar
- Gillingwater TH, Haley JE, Ribchester RR, Horsborough K: Neuroprotection after transient global ischaemia in Wld(s) mutant mice. J Cereb Blood Flow Metab. 2004, 24: 62-66. 10.1097/01.WCB.0000095798.98378.34.View ArticlePubMedGoogle Scholar
- Samsam M, Mi W, Wessig C, Zielasek J, Toyka KV, Coleman MP, Martini R: The Wlds mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy. Journal of Neuroscience. 2003, 23: 2833-2839.PubMedGoogle Scholar
- Adalbert R, Gillingwater TH, Haley JE, Bridge K, Beirowski B, Berek L, Wagner D, Grumme D, Thomson D, Celik A, Addicks K, Ribchester RR, Coleman MP: A rat model of slow Wallerian degeneration (WldS) with improved preservation of synapses. European Journal of Neuroscience. 2005, 21: 271-7. 10.1111/j.1460-9568.2004.03833.x.View ArticlePubMedGoogle Scholar
- MacDonald JM, Beach MG, Porpiglia E, Sheehan AE, Watts RJ, Freeman MR: The Drosphila cell corpse engulfment receptor Draper mediates glial clearance of severed axons. Neuron. 2006, 50: 869-881. 10.1016/j.neuron.2006.04.028.View ArticlePubMedGoogle Scholar
- Wang MS, Fang G, Culver DG, Davis AA, Rich MM, Glass JD: The Wlds protein protects against axonal degeneration: a model of gene therapy for peripheral neuropathy. Annules of Neurology. 2001, 50: 773-779. 10.1002/ana.10039.View ArticleGoogle Scholar
- Wishart TM, Paterson JM, Short DM, Meredith S, Robertson KA, Sutherland C, Cousin MA, Dutia MB, Gillingwater TH: Differential proteomic analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene. Mol Cell Proteomics. 2007, 6: 1318-1330. 10.1074/mcp.M600457-MCP200.PubMed CentralView ArticlePubMedGoogle Scholar
- Gillingwater TH, Wishart TM, Chen PE, Haley JE, Robertson K, MacDonald SH, Middleton S, Wawrowski K, Shipston MJ, Melmed S, Wyllie DJ, Skehel PA, Coleman MP, Ribchester RR: The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells. Hum Mol Genet. 2006, 15: 625-635. 10.1093/hmg/ddi478.View ArticlePubMedGoogle Scholar
- Mack TGA, Reiner M, Beirowski B, Mi W, Emanuelli M, Wagner D, Thomson D, Gillingwater T, Court F, Conforti L, Fernando FS, Tarlton A, Andressen C, Addicks K, Magni G, Ribchester RR, Perry VH, Coleman MP: Wallerain degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nature Neuroscience. 2001, 4: 1199-1206. 10.1038/nn770.View ArticlePubMedGoogle Scholar
- Conforti L, Tarlton A, Mack TGA, Mi W, Buckmaster EA, Wagner D, Perry VH, Coleman MP: A Ufd2/D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian degeneration (WldS) mouse. PNAS. 2000, 97: 11377-11382. 10.1073/pnas.97.21.11377.PubMed CentralView ArticlePubMedGoogle Scholar
- Mi W, Conforti L, Coleman MP: Genotyping Methods to Detect a Unique Neuroprotective Factor (Wlds) for Axons. Journal of Neuroscience Research. 2002, 113: 215-218.Google Scholar
- Laird PW, Zijderveld A, Linders K, Rudnicki MA, Jaenisch R, Berns A: Simplified mammalian DNA isolation procedure. Nucleic Acids Research. 1991, 19: 4293-4297. 10.1093/nar/19.15.4293.PubMed CentralView ArticlePubMedGoogle Scholar
- Ballester M, Castello A, Sanchez A, Folch JM: Real-time quantitative PCR based system for determining transgene copy number in transgenic animals. BioTechniques. 2004, 37: 610-613.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.